Neumora Therapeutics, Inc. Common Stock / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €222.99M +183.5% -€52.61M -67.2% -23.6% +1.8 pp N/A N/A
    (estimated) €78.66M +337.9% -€160.62M -11.1% -204.2% +8.0 pp N/A N/A
    (estimated) €17.96M +517.1% -€180.76M +9.2% -1,006.4% +47 pp -€104.55M -6.6% -582.1% +33 pp
    (estimated) €2.91M +∞% -€165.53M -15.6% -5,686.8% -57 pp -€111.92M -30.2% -3,845.0% -38 pp
    (estimated) €0.00 +NaN% -€196.15M -6.0% N/A -€160.35M +2.4% N/A
    €0.00 +NaN% -€208.70M +3.3% N/A -€156.61M +12.1% N/A
    €0.00 +NaN% -€201.97M +80.2% N/A -€139.68M +42.6% N/A
    €0.00 +NaN% -€112.07M -44.8% N/A -€97.92M +53.3% N/A
    €0.00 +NaN% -€203.16M +139.1% N/A -€63.87M +193.0% N/A
    €0.00 -€84.99M N/A -€21.80M N/A

    Notifications